Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Convertible Debt (2020 - 2025)

Historic Convertible Debt for BridgeBio Pharma (BBIO) over the last 6 years, with Q2 2025 value amounting to $739.9 million.

  • BridgeBio Pharma's Convertible Debt rose 27.0% to $739.9 million in Q2 2025 from the same period last year, while for Jun 2025 it was $739.9 million, marking a year-over-year increase of 27.0%. This contributed to the annual value of $738.9 million for FY2024, which is 26.69% up from last year.
  • Latest data reveals that BridgeBio Pharma reported Convertible Debt of $739.9 million as of Q2 2025, which was up 27.0% from $739.4 million recorded in Q1 2025.
  • BridgeBio Pharma's Convertible Debt's 5-year high stood at $739.9 million during Q2 2025, with a 5-year trough of $731.7 million in Q1 2021.
  • Its 5-year average for Convertible Debt is $735.7 million, with a median of $735.7 million in 2023.
  • In the last 5 years, BridgeBio Pharma's Convertible Debt skyrocketed by 9834.68% in 2021 and then rose by 25.06% in 2022.
  • BridgeBio Pharma's Convertible Debt (Quarter) stood at $733.1 million in 2021, then increased by 0.25% to $735.0 million in 2022, then increased by 0.26% to $736.9 million in 2023, then grew by 0.27% to $738.9 million in 2024, then rose by 0.14% to $739.9 million in 2025.
  • Its Convertible Debt was $739.9 million in Q2 2025, compared to $739.4 million in Q1 2025 and $738.9 million in Q4 2024.